TherapeuticsMD Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
$0.20next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
License Revenue Annually3M
Cash and Cash Equivalents Quarterly8.4M
Net Income (Loss) from Continuing Operations Quarterly103K
Watch Items
- Evaluation of Strategic AlternativesTrigger: Execution of a definitive agreement for acquisition, merger, or asset saleAction: Re-evaluate investment thesis based on transaction terms and valuation
- Mayne Pharma Commercial PerformanceTrigger: Significant decline in sales of IMVEXXY, BIJUVA, or ANNOVERAAction: Adjust royalty revenue projections and assess impairment risks of intangible assets
- Ongoing Disputes with Mayne PharmaTrigger: Adverse legal ruling or settlement in the Delaware lawsuitAction: Assess financial impact on cash reserves and future royalty streams
Research as of 20 Jun 2026